Cresilon is a New York-based biotechnology company that develops, manufactures, and markets hemostatic medical devices using a proprietary gel technology. Its lead product, VETIGEL, is a hemostatic gel for the animal health market that instantly stops bleeding in a variety of emergency care and surgical applications. The company plans to increase production capacity at its biomanufacturing facility in Brooklyn to support growth and the recent launch of VETIGEL. Management intends to use new funding to accelerate a global growth plan and expand commercial activity. Cresilon has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration to support entry into the human health market using its hemostatic gel technology. The company is led by CEO Joe Landolina.

Total raised

$25M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2022